$126 Million is the total value of Abingworth LLP's 16 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 5.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | Sell | Crisprnamen akt | $38,970,000 | -31.2% | 2,444,809 | -6.0% | 31.01% | -26.5% |
| PRTK | Sell | Paratek | $31,275,000 | +24.8% | 1,300,432 | -0.1% | 24.89% | +33.3% |
| SIEN | Sientra | $21,330,000 | +15.6% | 2,199,012 | 0.0% | 16.98% | +23.5% | |
| CBAY | Cymabay | $9,216,000 | +34.3% | 1,600,000 | 0.0% | 7.33% | +43.4% | |
| CASC | Cascadian | $3,432,000 | -10.4% | 925,000 | 0.0% | 2.73% | -4.3% | |
| IMDZ | Immune Design | $3,400,000 | +43.0% | 352,300 | 0.0% | 2.71% | +52.7% | |
| PRTO | Proteon | $3,027,000 | -11.7% | 2,017,872 | 0.0% | 2.41% | -5.8% | |
| CHMA | Chiasma | $2,913,000 | -17.6% | 2,080,595 | 0.0% | 2.32% | -12.0% | |
| CLLS | Cellectissponds adr | $2,566,000 | +6.9% | 100,000 | 0.0% | 2.04% | +14.2% | |
| DERM | Dermira | $2,038,000 | -14.6% | 70,000 | 0.0% | 1.62% | -8.8% | |
| EVAR | Lombard Medical | $1,806,000 | -33.3% | 3,473,452 | 0.0% | 1.44% | -28.8% | |
| HSGX | Histogenix | $1,582,000 | +7.2% | 888,889 | 0.0% | 1.26% | +14.5% | |
| AUPH | Aurinia Pharma | $1,543,000 | -16.5% | 252,129 | 0.0% | 1.23% | -10.8% | |
| INNL | Innocollsponds adr | $1,220,000 | +108.2% | 537,235 | 0.0% | 0.97% | +122.2% | |
| ADAP | Adaptimmunesponds adr | $1,125,000 | -18.2% | 250,000 | 0.0% | 0.90% | -12.6% | |
| NOVN | Novan | $215,000 | -36.2% | 53,367 | 0.0% | 0.17% | -31.9% | |
| SENS | Exit | Senseonics | $0 | – | -516,882 | -100.0% | -0.68% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
| 13F-HR | 2022-11-10 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.